"Integral Molecular is supporting the global response to COVID-19 by employing the processing power of the iQue in the discovery and characterization of SARS-CoV2 therapies. Integral Molecular’s projects employ three key technologies that rely on high-throughput flow cytometry to assist in the rapid development of therapeutics against COVID-19."
"The Shotgun Mutagenesis Epitope Mapping is using SARS-Cov2 MAbs to reveal their mechanism of action and learn how vaccines and the human immune system can effectively neutralize the virus. Integral Molecular is using the Membrane Proteome Array™ (MPA) to de-risk therapeutic antibodies by performing antibody specificity testing. The unique live-cell technology MPA can be used in functional genomic screens to identify novel receptors used by SARS-CoV2. Finally, Integral Molecular is developing reporter virus particles (RVPs) of SARS-CoV2."
Integral Molecular is the industry leader in epitope mapping and antibody discovery, with a pipeline of therapeutic antibodies against GPCRs, ion channels, transporters, and immuno-oncology targets. Built on the company’s extensive experience optimizing membrane proteins, Integral Molecular’ s technology suite enables the isolation, characterization, and engineering of MAbs against otherwise intractable targets. The company currently has therapeutic programs focused on cancer, pain, immunity, and metabolic diseases
Integral Molecular is utilizing our high-throughput flow cytometry platform to speed their Antibody screening and discovery efforts for COVID-19.
"Humane Genomics uses the Incucyte Live-Cell analysis to evaluate a non-pathological virus (VSV) infectivity of cells that express the ACE-2 with the goals to elucidate an immune response without side effects. Visit the blog to watch the video showing that the vaccine is binding the ACE2 receptor, based on co-localization of the labeled ACE-2 receptor (red) and the attenuated virus (green labeled Spike S protein)."
"The more we use the Incucyte, the more we can appreciate the amount of applications that we can use to evaluate our research models. We have realized that the learning from our viral development assays have been accelerated due to insights gained by using imaged-based analysis offered by the Incucyte system."
At Humane Genomics, we are pioneering synthetic virology to deliver precision cancer therapies and ensure humane care.
Chad Moles, M.S., Biotechnology | Chief Scientific Officer & Co-Founder Humane Genomics Inc
University of Edinburgh
"Within our COVID-19 research, we are looking to develop inflammatory assays using the Incucyte, specifically around monocyte, macrophage and neutrophil activation. Different drugs will be tested in order to provide information to the clinicians concerning potential subsequent lung tissue scaring and long-term effects on patients, in order to identify optimal drug treatments"